To Provide Update on AXT107 Duration of Efficacy Maintained for Over Thirteen Months to Date in Animal Models AXT107 Inhibits…
Read More
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European…
